![](/images/Company_Logo/company_logo_default.png)
Vajra Instruments Inc Profile last edited on: 5/17/18
CAGE: 58T28
UEI: JBD3P7YDM244
Business Identifier: Early Detection of Pancreatic Cancer Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Lancaster
Congr. District: 01
County: Lancaster
Public Profile
Vajra Instruments Inc is focused on an inexpensive screening tool for pancreatic cancer. Recent research indicates that less than hundred microRNA (miRNA) sequences specifically generated by tumors are sufficient for early detection of PaC and other cancers for effective intervention with excellent prognosis MiRNA can be extracted from urine and blood using standard kits. The key challenge is to detect specific biomarkers in the thousand fold large background of miRNA sequences that body normally produces. While quantitative reverse transcribe polymerase chain reaction qRT PCR is an effective tool for miRNA profiling it is prohibitively expensive for screening. The firm is working to directly measure the tumor specific miRNA extracted from about ml of serum or plasma using a disruptive technology called SEED. Measurement by SEED is virtually blind to non specific binding with consistency. The binding time of targeted miRNA to the probe will reduce from hours for conventional microarray methods to below one hour.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2019 | 2 | NIH | $2,292,516 | |
Project Title: Profiling Circulating miRNA Without PCR for Early Detection of Pancreatic Cancer | ||||
2018 | 1 | NIH | $280,000 | |
Project Title: Rapid mRNA Expression Analysis by Quantitative Electrochemical Microarray at Sub-Zeptomole Levels without PCR and Labels | ||||
2017 | 1 | NIH | $299,715 | |
Project Title: Low-Cost, Handheld Tactile Imaging Device for Breast Cancer Screening |
Key People / Management
Santanu Saraf Roy
Ravi Saraf
Ravi Saraf
Company News
There are no news available.